How long does yervoy related fatigue typically last?

How long does Yervoy-related fatigue typically last?

Yervoy (ipilimumab) fatigue usually develops during treatment and persists for weeks to months after the final dose. Most patients see improvement within 4–12 weeks once therapy ends, but some experience it for 6 months or longer.

Why does this fatigue occur with Yervoy?

Ipilimumab blocks CTLA-4, which removes a brake on the immune system. The resulting immune activation can cause widespread inflammation and cytokine release that affects energy levels. This is distinct from chemotherapy fatigue, which often occurs during infusion weeks.

What factors make fatigue last longer?

Patients who receive combination therapy with Opdivo (nivolumab) or higher doses of Yervoy tend to report more persistent fatigue. Older age, low baseline hemoglobin, and prior radiation also increase duration. Endocrine irAEs such as hypothyroidism can prolong recovery if they are not managed promptly.

Can fatigue return after it appears to have resolved?

Yes. Late-onset or recurring fatigue can appear months after finishing Yervoy. This is rarer but occurs mainly in patients who had severe immune-related adverse events during treatment.

How does Yervoy fatigue compare with Opdivo alone?

Yervoy monotherapy produces similar fatigue rates to Opdivo, but the combination raises incidence and duration. Data show 40–50% of patients on Yervoy alone report fatigue versus 30–35% on Opdivo alone. The combination pushes rates above 50%, above 50%, and sometimes extends recovery beyond 6 months.

What treatments help shorten recovery time?

Corticosteroids are used for moderate to severe cases. Supportive care—rest, light exercise, nutrition counseling, and thyroid hormone replacement when needed—shortens recovery.